Meat-based Versus Pesco-vegetarian Diet and Colorectal Cancer (MeaTIc)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03416777 |
|
Recruitment Status :
Completed
First Posted : January 31, 2018
Last Update Posted : July 30, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Nutrition Aspect of Cancer Diet Modification Cancer of Colon | Behavioral: Meat-based diet Dietary Supplement: Meat-based diet supplemented with alpha-tocopherol (MBD-T) Behavioral: Pesco-vegetarian diet | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 103 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Randomized parallel open dietary intervention study with 3 arms of intervention |
| Masking: | None (Open Label) |
| Masking Description: | In this trial blinding of participants and investigators will not be possible because of obvious differences between the intervention diets |
| Primary Purpose: | Prevention |
| Official Title: | Faecal Microbiome as Determinant of the Effect of Diet on Colorectal-cancer Risk: Comparison of Meat Based Versus Pesco-vegetarian Diets (MeaTIc) |
| Actual Study Start Date : | June 1, 2019 |
| Actual Primary Completion Date : | December 31, 2019 |
| Actual Study Completion Date : | April 30, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Meat-based diet (MBD)
Behavioral intervention with diet including 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat.
|
Behavioral: Meat-based diet
Diet including 4 servings per week of red meat (1 serving = 150 g), 3 servings per week of processed meat (1 serving = 50 g), and 1 servings per week of poultry (1 serving = 150 g), for a total amount of 900 g per week of meat.
Other Name: MBD |
|
Experimental: Meat-based alpha-tocopherol (MBD-T)
Behavioral intervention including diet with 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat with a dietary supplement of 100 mg/day of alpha-tocopherol in the form of tablet
|
Dietary Supplement: Meat-based diet supplemented with alpha-tocopherol (MBD-T)
Dietary intervention like the MBD with supplementation of alpha-tocopherol at a dosage of 100 mg/die. Available evidence suggests that alpha-tocopherol may help prevent colon cancer by decreasing the formation of mutagens arising from the oxidation of faecal lipids, by decreasing oxidative stress in the epithelial cells of the colon and by molecular mechanisms that influence cell death, cell cycle and transcriptional events (Pierre 2013, Bastide 2016, Bastide 2017, Diallo 2016). It is important to note that 200 mg/day of tocopherol was administered to 20,000 women for 10 years without side effects (Lee et al.,2005).
Other Name: MBD-T |
|
Experimental: Pesco-vegetarian (PVD)
Behavioral intervention with diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish
|
Behavioral: Pesco-vegetarian diet
Diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish (1 serving = 150 g), for a total amount of 450 g per week. Diet will contain other sources of proteins (e.g. eggs, dairy, legumes/beans). There is suggestive evidence that fish and vegetable consumption has protective effects against CRC (Vieira et al., 2017).
Other Name: PVD |
- DNA damage [ Time Frame: 3 months ]Decrease (<25%) of DNA damage by faecal water (genotoxicity), using comet assay in a cellular model
- Microbiome and metabolomics profiles [ Time Frame: 3 months ]Changes of microbiome and the relative metabolomics profiles from baseline
- Peroxidation [ Time Frame: 3 months ]Global and specific peroxidation of omega-3 and omega-6 of the faecal water change from baseline
- Inflammatory parameters [ Time Frame: 3 months ]Pro- and anti-inflammatory profile's change from baseline
- Oxidative stress [ Time Frame: 3 months ]Oxidative stress profile's change from baseline
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- clinically healthy (both sexes)
- age >18 years and ≤ 50 years.
The study population will be selected with an age ranging from 18 to 50 years because after 50 years the risk for CRC shows a significant increase in incidence. In fact, more than 90% of the people diagnosed with the disease are older than 50, with the average age at the time of diagnosis being 64 (Amersi et al., 2005). With respect to gender, its role in the development of colorectal cancer remains unclear (Amersi et al., 2005).
Exclusion Criteria:
- Presence of current illness or unstable conditions
- Current or recent (past 2 months) use of antibiotics or probiotics
- Pregnancy or intention to become pregnant in the next 12 months or lactation
- Current smoking habit
- Current or recent (past 2 months) adoption of a vegetarian diet
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03416777
| Italy | |
| Unit of Clinical Nutrition, University Hospital of Careggi | |
| Florence, Italy, 50134 | |
| Study Director: | Alessandro Casini, MD | University of Florence |
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Francesco Sofi, Associate Professor of Clinical Nutrition, Azienda Ospedaliero-Universitaria Careggi |
| ClinicalTrials.gov Identifier: | NCT03416777 |
| Other Study ID Numbers: |
MeaTIC-INTIMIC |
| First Posted: | January 31, 2018 Key Record Dates |
| Last Update Posted: | July 30, 2021 |
| Last Verified: | July 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
vegetarian meat fish |
|
Colonic Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases |
Tocopherols Vitamin E Tocotrienols alpha-Tocopherol Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Vitamins Micronutrients |

